Download PDF
Z Gastroenterol 2003; 41(11): 1101-1110
DOI: 10.1055/s-2003-44304
Übersicht
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Immunobiology and Gene-Based Immunotherapy of Hepatocellular Carcinoma

Immunbiologie und Immuntherapie des hepatozellulären KarzinomsM. Geissler1 , L. Mohr1 , M. Y. Ali1 , C. F. Grimm1 , M. Ritter1 , H . E. Blum1
  • 1Department of Medicine II, University Hospital Freiburg, Freiburg, Germany
Further Information

Publication History

Manuscript received: 3. April 2003

Accepted after revision: 17. April 2003

Publication Date:
01 December 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Einleitung: Das hepatozelluläre Karzinom (HCC) ist einer der häufigsten Tumoren weltweit mit ca. 1 Million Neuerkrankungen pro Jahr. Die Resektion und Lebertransplantation sind die bisher einzigen potenziell kurativen Therapieansätze in ausgewählten Fällen. Lokalablative Verfahren sind komplikationsarm, aber häufig mit Lokalrezidiven, intrahepatischen Metastasen oder neuen HCC-Herden in der zirrhotischen Leber assoziiert. Deshalb sind neue therapeutische Ansätze gegen das HCC und ein verbessertes Verständnis der HCC-Immunbiologie von hoher Priorität. In diesem Artikel sollen neue molekulare Therapieansätze zur Behandlung des HCC und die dafür notwendigen immunpathogenetischen Zusammenhänge dargestellt werden. Material und Methoden: Eine systematische Medline-Literatursuche wurde in allen zitierten Sprachen ab 1970 durchgeführt. Ergebnisse: Eine Vielzahl spezifischer und unspezifischer immunstimulierender Strategien gegen das HCC wurde bisher in präklinischen experimentellen Modellen mit viel versprechenden Resultaten untersucht. Obwohl die bisherigen tumorimmuntherapeutischen Ansätze nur mäßigen klinischen Erfolg bei verschiedenen Tumorentitäten zeigten, konnten mittels neuer molekularer Methoden in den letzten Jahren neue Tumorantigene wie das α-Fetoprotein (AFP) identifiziert werden. Das verbesserte Verständnis der Tumorimmunbiologie ist der Grundstein für eine erfolgreiche Immuntherapie von Tumoren. Erste klinische Phase-I- und -II-Studien mit dem Ziel einer HCC-Immuntherapie unter Verwendung dendritischer Zellen als zelluläres Adjuvans zur Tumorantigenvakzinierung sind inzwischen initiiert. Eine Korrelation von klinischem Verlauf und Monitoring der Immuneffektoren nach Tumorvakzinierung kann mittels neuer immunologischer Techniken, die Immuneffektoren auf Einzelzellebene charakterisieren und in vivo verfolgen können, durchgeführt werden. Zukünftige immuntherapeutische klinische Studien lassen prognostische Parameter für bestimmte Patientenuntergruppen, optimierte Vakzinierungsprotokolle und neue immunologisch-molekulare Surrogatmarker für die Diagnostik von HCCs erwarten.

Abstract

Purpose: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide. For most patients with advanced or multifocal HCC treatment options are limited resulting in a poor prognosis. Several local ablation methods have been developed as minimally invasive strategies for HCC treatment. It is unclear, until now, whether these therapies will significantly improve the poor prognosis of patients with unresectable HCC. Novel therapeutic strategies and a better understanding of HCC imunobiology are, therefore, urgently required.

Design: The scientific literature since 1970 in all languages cited in Medline was systematically reviewed. Results: Until now, a variety of specific and non-specific immunostimulatory strategies against HCC has been applied in preclinical experimental models with some promising results. The molecular characterization of HCC associated tumour antigens such as α-fetoprotein (AFP) and the increased understanding of the immunological pathways involved in liver and tumor immunology have paved the way for the design of promising gene-based cancer vaccines. The first phase I and II immunotherapeutic clinical trials based on dendritic cell immunotherapy and peptide vaccines are ongoing in HCC-patients. Clinical trials have, in general, demonstrated the safety of such strategies. Recently, exciting new immunological techniques and tools have been developed which allow to characterize antigen specific T cells at a single-cell level. In future, HCC specific tumor rejection antigens which can be used therapeutically have to be identified using microarray-based analysis. The different therapeutic modalities need to be compared directly resulting in optimised therapeutic approaches and the identification of sub-groups of HCC-patients responding favourably to treatment.

Schlüsselwörter

HCC - Immuntherapie - Gentherapie - Zytokine - dendritische Zellen - T-Zelle

Key words

HCC - immunotherapy - gene therapy - dendritic cells - T cell - cytokines

References

  • 1 Bosch F X, Ribes J, Borras J. Epidemiology of primary liver cancer.  Sem Liv Dis. 1999;  19 271-285
    Google Scholar
  • 2 De Vos I, Goldberg D, Hole D J. et al . Trends in primary liver cancer.  Lancet. 1998;  351 215-216
    Google Scholar
  • 3 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  340 745-750
    Google Scholar
  • 4 Okuda K. Early recognition of hepatocellular carcinoma.  Hepatology. 1986;  6 729-738
    Google Scholar
  • 5 Bismuth H, Chiche L, Adam R. et al . Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients.  Ann Surg. 1993;  218 145-151
    Google Scholar
  • 6 Allgaier H P, Galandi D, Zuber I. et al . Radiofrequency thermal ablation of hepatocellular carcinoma.  Dig Dis. 2001;  19 301-310
    Google Scholar
  • 7 Mohr L, Geissler M, Blum H E. Gene therapy for malignant liver disease.  Expert Opin Biol Ther. 2002;  2 163-175
    Google Scholar
  • 8 Geissler M, Mohr L, Blum H E. Immunotherapy of hepatocellular carcinoma.  Dtsch Med Wochenschr. 2001;  126 1464-1466
    Google Scholar
  • 9 Butterfield L H, Ribas A. Immunotherapy of hepatocellular carcinoma.  Expert Opin Biol Ther. 2002;  2 123-133
    Google Scholar
  • 10 Yee C, Riddell S R, Greenberg P D. Prospects for adoptive T cell therapy.  Curr Opin Immunol. 1997;  9 702-708
    Google Scholar
  • 11 Renner C, Kubuschok B, Trumper L. et al . Clinical approaches to vaccination in oncology.  Ann Hematol. 2001;  80 255-266
    Google Scholar
  • 12 Wild C P, Hall A J. Primary prevention of hepatocellular carcinoma in developing countries.  Mutat Res. 2000;  462 381-393
    Google Scholar
  • 13 Schultze J L, Maecker B, von Bergwelt-Baildon M S. et al . Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.  Vox Sang. 2001;  80 81-89
    Google Scholar
  • 14 Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens.  Semin Immunol. 1996;  8 289-293
    Google Scholar
  • 15 Kurokohchi K, Carrington M, Mann D L. et al . Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma.  Hepatology. 1996;  23 1181-1188
    Google Scholar
  • 16 Ricci G, Colombo C, Ghiazza B. et al . HLA-A, B, C, DR and DQ expression and hepatocellular carcinoma: study of 205 Italian subjects.  Cancer Lett. 1995;  98 121-125
    Google Scholar
  • 17 Paterson A C, Sciot R, Kew M C. et al . HLA expression in human hepatocellular carcinoma.  Br J Cancer. 1988;  57 369-373
    Google Scholar
  • 18 Nagao M, Nakajima Y, Kanehiro H. et al . The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma.  Hepatology. 2000;  32 491-500
    Google Scholar
  • 19 Kanzler S, Meyer E, Lohse A W. et al . Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis.  Oncogene. 2001;  20 5015-5024
    Google Scholar
  • 20 Bissell D M, Roulot D, George J. Transforming growth factor beta and the liver.  Hepatology. 2001;  34 859-867
    Google Scholar
  • 21 Gorelik L, Fields P E, Flavell R A. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.  J Immunol. 2000;  165 4773-4777
    Google Scholar
  • 22 Gorelik L, Flavell R A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease.  Immunity. 2000;  12 171-181
    Google Scholar
  • 23 Kim K Y, Jeong S Y, Won J. et al . Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma.  J Biol Chem. 2001;  276 38781-38786
    Google Scholar
  • 24 Maggard M, Meng L, Ke B. et al . Antisense TGF-beta2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model.  Ann Surg Oncol. 2001;  8 32-37
    Google Scholar
  • 25 Gorelik L, Flavell R A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.  Nat Med. 2001;  7 1118-1122
    Google Scholar
  • 26 Nagao M, Nakajima Y, Hisanaga M. et al . The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?.  Hepatology. 1999;  30 413-421
    Google Scholar
  • 27 Patel T. Immune escape in hepatocellular cancer: is a good offense the best defense?.  Hepatology. 1999;  30 576-578
    Google Scholar
  • 28 Strand S, Hofmann W J, Hug H. et al . Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion?.  Nat Med. 1996;  2 1361-1366
    Google Scholar
  • 29 Galle P R, Hofmann W J, Walczak H. et al . Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.  J Exp Med. 1995;  182 1223-1230
    Google Scholar
  • 30 Weidmann E, Whiteside T L, Giorda R. et al . The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.  Cancer Res. 1992;  52 5913-5920
    Google Scholar
  • 31 Takagi S, Chen K, Schwarz R. et al . Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2.  Cancer. 1989;  63 102-111
    Google Scholar
  • 32 Wada Y, Nakashima O, Kutami R. et al . Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration.  Hepatology. 1998;  27 407-414
    Google Scholar
  • 33 Zhang L, Conejo-Garcia J R, Katsaros D. et al . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.  N Engl J Med. 2003;  348 203-213
    Google Scholar
  • 34 Shields P L, Morland C M, Salmon M. et al . Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.  J Immunol. 1999;  163 6236-6243
    Google Scholar
  • 35 Yoong K F, McNab G, Hubscher S G. et al . Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma.  J Immunol. 1998;  160 3978-3988
    Google Scholar
  • 36 Yoong K F, Afford S C, Jones R. et al . Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma.  Hepatology. 1999;  30 100-111
    Google Scholar
  • 37 Pockaj B A, Sherry R M, Wei J P. et al . Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.  Cancer. 1994;  73 1731-1737
    Google Scholar
  • 38 Yoneyama H, Matsuno K, Zhang Y. et al . Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease.  J Exp Med. 2001;  193 35-49
    Google Scholar
  • 39 Chen S, Akbar S M, Tanimoto K. et al . Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis.  Cancer Lett. 2000;  148 49-57
    Google Scholar
  • 40 Ninomiya T, Akbar S M, Masumoto T. et al . Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma.  J Hepatol. 1999;  31 323-331
    Google Scholar
  • 41 Kakumu S, Ito S, Ishikawa T. et al . Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection.  J Gastroenterol Hepatol. 2000;  15 431-436
    Google Scholar
  • 42 Knolle P A, Limmer A. Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells.  Trends Immunol. 2001;  22 432-437
    Google Scholar
  • 43 Abe M, Akbar S M, Horiike N. et al . Induction of cytokine production and proliferation of memory lymphocytes by murine liver dendritic cell progenitors: role of these progenitors as immunogenic resident antigen-presenting cells in the liver.  J Hepatol. 2001;  34 61-67
    Google Scholar
  • 44 Chuma M, Sakamoto M, Yamazaki K. et al . Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma.  Hepatology. 2003;  37 198-207
    Google Scholar
  • 45 Chung E J, Sung Y K, Farooq M. et al . Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray.  Mol Cells. 2002;  14 382-387
    Google Scholar
  • 46 Dominguez-Malagon H, Gaytan-Graham S. Hepatocellular carcinoma: an update.  Ultrastruct Pathol. 2001;  25 497-516
    Google Scholar
  • 47 Delpuech O, Trabut J B, Carnot F. et al . Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma.  Oncogene. 2002;  21 2926-2937
    Google Scholar
  • 48 Li Y, Tang R, Xu H. et al . Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays.  J Cancer Res Clin Oncol. 2002;  128 369-379
    Google Scholar
  • 49 Xu X R, Huang J, Xu Z G. et al . Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver.  Proc Natl Acad Sci U S A. 2001;  98 15089-15094
    Google Scholar
  • 50 Yamashita T, Hashimoto S, Kaneko S. et al . Comprehensive gene expression profile of a normal human liver.  Biochem Biophys Res Commun. 2000;  269 110-116
    Google Scholar
  • 51 Guo J, Cai M, Wei D. et al . Immune responses of dendritic cells after loaded with cytotoxicity T lymphocyte epitope based peptide of human alpha-fetoprotein (hAFP).  Zhonghua Gan Zang Bing Za Zhi. 2002;  10 178-180
    Google Scholar
  • 52 Hanke P, Rabe C, Serwe M. et al . Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein.  Scand J Gastroenterol. 2002;  37 949-955
    Google Scholar
  • 53 Geissler M, Mohr L, Köhler G. et al . Immunotherapy Directed Against alpha-Fetoprotein Results in Autoimmune Liver Disease During Liver Regeneration in Mice.  Gastroenterology. 2001;  121 931-939
    Google Scholar
  • 54 Butterfield L H, Koh A, Meng W. et al . Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.  Cancer Res. 1999;  59 3134-3142
    Google Scholar
  • 55 Butterfield L H, Meng W S, Koh A. et al . T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.  J Immunol. 2001;  166 5300-5308
    Google Scholar
  • 56 Meng W S, Butterfield L H, Ribas A. et al . Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.  Mol Immunol. 2000;  37 943-950
    Google Scholar
  • 57 Meng W S, Butterfield L H, Ribas A. et al . alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.  Cancer Res. 2001;  61 8782-8786
    Google Scholar
  • 58 Lee W C, Wang H C, Jeng L B. et al . Effective treatment of small murine hepatocellular carcinoma by dendritic cells.  Hepatology. 2001;  34 896-905
    Google Scholar
  • 59 Homma S, Toda G, Gong J. et al . Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice.  J Gastroenterol. 2001;  36 764-771
    Google Scholar
  • 60 Vollmer C M Jr, Eilber F C, Butterfield L H. et al . Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.  Cancer Res. 1999;  59 3064-3067
    Google Scholar
  • 61 Ladhams A, Schmidt C, Sing G. et al . Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells.  J Gastroenterol Hepatol. 2002;  17 889-896
    Google Scholar
  • 62 Chan R C, Xie H, Zhao G P. et al . Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes.  Immunol Lett. 2002;  83 101-109
    Google Scholar
  • 63 Grimm C F, Ortmann D, Mohr L. et al . Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice.  Gastroenterology. 2000;  119 1104-1112
    Google Scholar
  • 64 Schlott T, Ahrens K, Ruschenburg I. et al . Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia.  Br J Cancer. 1999;  80 73-78
    Google Scholar
  • 65 Kobayashi Y, Higashi T, Nouso K. et al . Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma.  J Hepatol. 2000;  32 612-617
    Google Scholar
  • 66 Chen Y T, Scanlan M J, Sahin U. et al . A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.  Proc Natl Acad Sci U S A. 1997;  94 1914-1918
    Google Scholar
  • 67 Mohr L, Schauer J I, Boutin R H. et al . Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery system.  Hepatology. 1999;  29 82-89
    Google Scholar
  • 68 Moradpour D, Compagnon B, Wilson B E. et al . Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro.  Hepatology. 1995;  22 1527-1537
    Google Scholar
  • 69 Tanaka S, Wands J R. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis.  Cancer Res. 1996;  56 3391-3394
    Google Scholar
  • 70 Nishiyama M, Wands J R. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma.  Biochem Biophys Res Commun. 1992;  183 280-285
    Google Scholar
  • 71 Ince N, de la Monte S M, Wands J R. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation.  Cancer Res. 2000;  60 1261-1266
    Google Scholar
  • 72 Lavaissiere L, Jia S, Nishiyama M. et al . Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.  J Clin Invest. 1996;  98 1313-1323
    Google Scholar
  • 73 Bergsland E K. Molecular mechanisms underlying the development of hepatocellular carcinoma.  Semin Oncol. 2001;  28 521-531
    Google Scholar
  • 74 Covini G, Chan E K, Nishioka M. et al . Immune response to cyclin B1 in hepatocellular carcinoma.  Hepatology. 1997;  25 75-80
    Google Scholar
  • 75 Yutani S, Shichijo S, Inoue Y. et al . Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas.  Oncol Rep. 2001;  8 369-372
    Google Scholar
  • 76 Noguchi K, Enjoji M, Nakamuta M. et al . Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma.  Cancer Lett. 2001;  168 197-202
    Google Scholar
  • 77 Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1.  Nat Med. 1999;  5 938-942
    Google Scholar
  • 78 Wang Y, Han K J, Pang X W. et al . Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies.  J Immunol. 2002;  169 1102-1109
    Google Scholar
  • 79 Chun E, Lee J, Cheong H S. et al . Tumor eradication by hepatitis B virus × antigen-specific CD8(+) T cells in xenografted nude mice.  J Immunol. 2003;  170 1183-1190
    Google Scholar
  • 80 Steerenberg P A, Geerse E, De Jong W H. et al . Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations.  Cancer Immunol Immunother. 1991;  34 103-110
    Google Scholar
  • 81 Takayama T, Makuuchi M, Sekine T. et al . Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report.  Cancer. 1991;  68 2391-2396
    Google Scholar
  • 82 Aruga A, Yamauchi K, Takasaki K. et al . Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization.  Int J Cancer. 1991;  49 19-24
    Google Scholar
  • 83 Onishi S, Saibara T, Fujikawa M. et al . Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.  Hepatology. 1989;  10 349-353
    Google Scholar
  • 84 Kanai T, Monden M, Takeda T. et al . Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2.  Gan To Kagaku Ryoho. 1993;  20 1457-1460
    Google Scholar
  • 85 Wang Y, Chen H, Wu M. et al . Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.  Chin Med J (Engl). 1997;  110 114-117
    Google Scholar
  • 86 Takayama T, Sekine T, Makuuchi M. et al . Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 802-807
    Google Scholar
  • 87 Friedl J, Stift A, Paolini P. et al . Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer.  Cancer Biother Radiopharm. 2000;  15 477-486
    Google Scholar
  • 88 Ilan Y, Gabay E, Amit G. et al . Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen.  J Hepatol. 1997;  27 170-175
    Google Scholar
  • 89 Romieu R, Baratin M, Kayibanda M. et al . Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model.  J Immunol. 1998;  161 5133-5137
    Google Scholar
  • 90 Siegel J P, Puri R K. Interleukin-2 toxicity.  J Clin Oncol. 1991;  9 694-704
    Google Scholar
  • 91 Suto T, Fukuda S, Moriya N. et al . Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma.  Cancer Chemother Pharmacol. 1994;  33 Suppl S145-S148
    Google Scholar
  • 92 Ichida T, Higuchi K, Arakawa K. et al . Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2.  Cancer Chemother Pharmacol. 1989;  23 Suppl S45-S48
    Google Scholar
  • 93 Uchino J, Une Y, Kawata A. et al . Postoperative chemoimmunotherapy for the treatment of liver cancer.  Semin Surg Oncol. 1993;  9 332-336
    Google Scholar
  • 94 Sangro B, Qian C, Schmitz V. et al . Gene therapy of hepatocellular carcinoma and gastrointestinal tumors.  Ann N Y Acad Sci. 2002;  963 6-12
    Google Scholar
  • 95 He P, Tang Z Y, Ye S L. et al . The targeted expression of interleukin-2 in human hepatocellular carcinoma cells.  J Exp Clin Cancer Res. 2000;  19 183-187
    Google Scholar
  • 96 Huang H, Chen S H, Kosai K. et al . Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo.  Gene Ther. 1996;  3 980-987
    Google Scholar
  • 97 Atarashi Y, Yasumura S, Nambu S. et al . A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma.  Hepatology. 1998;  28 57-67
    Google Scholar
  • 98 Cao G, Kuriyama S, Du P. et al . Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer.  Gastroenterology. 1997;  112 501-510
    Google Scholar
  • 99 Schmitz V, Barajas M, Wang L. et al . Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma.  Hepatology. 2001;  34 72-81
    Google Scholar
  • 100 Li Z, Sui Y, Jiang Y. et al . Reconstruction of SEA-B7.1 double signals on human hepatocellular carcinoma cells and analysis of its immunological effect.  Biochem Biophys Res Commun. 2001;  288 454-461
    Google Scholar
  • 101 Yamashita Y I, Shimada M, Hasegawa H. et al . Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model.  Cancer Res. 2001;  61 1005-1012
    Google Scholar
  • 102 Barajas M, Mazzolini G, Genove G. et al . Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.  Hepatology. 2001;  33 52-61
    Google Scholar
  • 103 Putzer B M, Stiewe T, Rodicker F. et al . Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes.  J Natl Cancer Inst. 2001;  93 472-479
    Google Scholar
  • 104 Tatsumi T, Takehara T, Kanto T. et al . B7 - 1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.  Hepatology. 1999;  30 422-429
    Google Scholar
  • 105 Wang Z, Qiu S J, Ye S L. et al . Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma.  Cancer Gene Ther. 2001;  8 751-758
    Google Scholar
  • 106 Andrews K J, Ribas A, Butterfield L H. et al . Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.  Cancer Res. 2000;  60 6457-6464
    Google Scholar
  • 107 Kroger A, Ortmann D, Krohne T U. et al . Growth suppression of the hepatocellular carcinoma cell line Hepa1 - 6 by an activatable interferon regulatory factor-1 in mice.  Cancer Res. 2001;  61 2609-2617
    Google Scholar
  • 108 Narvaiza I, Mazzolini G, Barajas M. et al . Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.  J Immunol. 2000;  164 3112-3122
    Google Scholar
  • 109 Martinet O, Ermekova V, Qiao J Q. et al . Immunomodulatory gene therapy with interleukin 12 and 4 - 1BB ligand: long-term remission of liver metastases in a mouse model.  J Natl Cancer Inst. 2000;  92 931-936
    Google Scholar
  • 110 Geutskens S B, van der Eb M M, Plomp A C. et al . Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells.  Gene Ther. 2000;  7 1410-1416
    Google Scholar
  • 111 Bramson J L, Bodner C A, Graham R W. Activation of host antitumoral responses by cationic lipid/DNA complexes.  Cancer Gene Ther. 2000;  7 353-359
    Google Scholar
  • 112 Tatsumi T, Takehara T, Kanto T. et al . Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.  Cancer Res. 2001;  61 7563-7567
    Google Scholar
  • 113 Cao X, Wang J, Zhang W. et al . Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy.  J Cancer Res Clin Oncol. 1995;  121 457-462
    Google Scholar
  • 114 Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity.  J Immunol. 2000;  164 2214-2220
    Google Scholar
  • 115 Schueller G, Paolini P, Friedl J. et al . Heat treatment of hepatocellular carcinoma cells: increased levels of heat shock proteins 70 and 90 correlate with cellular necrosis.  Anticancer Res. 2001;  21 295-300
    Google Scholar
  • 116 Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells.  Nat Med. 1999;  5 1249-1255
    Google Scholar
  • 117 Shi Y, Zheng W, Rock K L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.  Proc Natl Acad Sci U S A. 2000;  97 14590-14595
    Google Scholar
  • 118 Geissler M, Ali M, Ritter M. et al . Local ablation of hepatocellular carcinoma results in activation of dendritic cells and tumor specific T cell responses.  Hepatology. 2002;  36 696A
    Google Scholar
  • 119 Boon T, Cerottini J C, van den Eynde B. et al . Tumor antigens recognized by T lymphocytes.  Annu Rev Immunol. 1994;  12 337-365
    Google Scholar
  • 120 Schultze J L, Vonderheide R H. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens.  Trends Immunol. 2001;  22 516-523
    Google Scholar
  • 121 Vonderheide R H, Schultze J L, Anderson K S. et al . Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.  Cancer Res. 2001;  61 8366-8370
    Google Scholar

Michael Geissler, M.D.

Department of Medicine II, University Hospital Freiburg

Hugstetter Straße 55

79106 Freiburg

Email: mgeissl@ukl.uni-freiburg.de